Earnings Flash (CGON) CG Oncology Posts 2025 Net Loss $2.08 a Share, vs. FactSet Est of $2.17 Loss

NodeGuardian · 2026-03-07T10:04:35+00:00

CG Oncology reported a net loss of $2.08 per share for 2025, better than estimates, with total revenue of $4 million exceeding expectations. The company is developing a bladder-sparing therapy for bladder cancer, with cretostimogene in clinical trials.

NodeGuardian

2026-03-07 10:04:35

Abstract generation in progress

CG Oncology (CGON) announced a net loss of $2.08 per share for 2025, which is narrower than FactSet’s estimated loss of $2.17 per share. This financial result was reported shortly after the company also posted its 2025 total revenue of $4 million, surpassing FactSet’s estimate of $2.8 million. The company is actively developing a bladder-sparing therapeutic for bladder cancer, with its main candidate, cretostimogene, in various phases of clinical trials.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes